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Abstract: Background: Both old age and institutionalization in aged care homes come with a 
significant risk of developing several long-term mental and neurological disorders, but there has 
been no definitive meta-analysis of data from studies to determine the pooled estimate of central 
nervous system (CNS) medicines use in aged care homes. We conducted this systematic review to 
summarize the use of CNS drugs among aged care homes residents. Methods: MEDLINE, EMBASE, 
CINAHL, Scopus, and International Pharmaceutical Abstracts (IPA) databases were searched 
(between 1 January 2000 and 31 December 2018) to identify population-based studies that reported 
the use of CNS medicines in aged care homes. Pooled proportions (with 95% confidence interval), 
according to study location were calculated. Results: A total of 89 studies reported the use of CNS 
medicines use in aged care. The pooled estimate of CNS drugs use varied according to country (from 
20.3% in Ireland to 49.0% in Belgium) and region (from 31.7% in North America to 42.5% in 
Scandinavia). The overall pooled estimate of psychotropic medicines use was highest in Europe 
(72.2%, 95% CI, 67.1–77.1%) and lowest in ANZ region (56.9%, 95% CI, 52.2–61.4%). The pooled 
estimate of benzodiazepines use varied widely from 18.9% in North America to 44.8% in Europe. 
The pooled estimate of antidepressants use from 47 studies was 38.3% (95% CI 35.1% to 41.6%) with 
highest proportion in North America (44.9%, 95% CI, 35.3–54.5%). Conclusion: The overall use of 
CNS drugs varied among countries, with studies from Australia-New Zealand reported the lowest 
use of CNS drugs. The criteria for prescribing CNS drugs in clinical practice should be evidence-
based. The criteria should be used not to prohibit the use of the listed medications but to support 
the clinical judgement as well as patient safety. 
Keywords: aged care homes; antipsychotics; antidepressants; antiepileptics; antiparkinsons; 
benzodiazepines; Central Nervous System; psychotropics 
 
1. Introduction 
Population ageing is defined as a shift in the age distribution of a population toward older ages 
[1]. In 2015, adults aged 60 years and older constituted about 12% of the global population (900 
million) [1]. Ageing population is projected to increase up to 1.4 billion by 2030 (16.5% of the global 
population) and up to 2.1 billion by 2050 (21.5% of the global population) [1]. Parallel to population 
ageing, the number of aged care homes (also referred to as “nursing homes” or “aged care facilities”) 
have grown rapidly during the past two decades to partially address the health care needs of older 
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adults [2]. About 12 million older adults needed long-term care facilities in 2012; and this figure is 
projected to increase to 27 million in 2050 [3].  
Old age and institutionalization in aged care homes come with a significant risk of developing 
several long-term chronic mental health conditions such as cognitive decline, depression, dementia 
and/or psychosis [4,5]. According to the National Council on Ageing, approximately 92% of elderly 
adults have at least one chronic disease and approximately 77% have at least two. Dementia is the 
most common cognitive health issue affecting approximately 47 million adults worldwide with a 
prediction of a three-fold increase in the number by 2050 [5]. According to the World Health 
Organization (WHO), over 15% of older adults over the age of 60 suffer from mental illness with 
depression being a common disorder, affecting nearly 7% of them [5]. An increase in the number of 
the ageing population could mean the need for more care homes/facilities to provide care for the 
older population who would need to be institutionalized in such facilities.  
Most medicines used to treat central nervous system (CNS) disorders i.e., psychotropics, 
antipsychotics, antidepressants, benzodiazepines, antiepileptics and antiparkinsons are associated 
with adverse drug events in older adults [6]. The risk of falling and fall-related fractures have been 
reported with all of the drugs mentioned above [7,8]. Additionally, these medicines are also 
associated with cognitive dysfunction and memory impairment [9]. 
Studies have summarized the use of CNS medicines in individual countries as well as particular 
region (s) of the world [5,6,10]. However, to the best of our knowledge, there is a lack of a definitive 
systematic review and meta-analysis of data from studies to determine the global estimate of CNS 
medicines use in aged care homes. Given the recent technological advances in telecommunication 
and data management, collaborations between various parts of the world have never been easier. 
Hence, a comparative study of CNS medicines across various regions and countries of the world will 
not only provide a useful baseline measure to compare the proportions of CNS medicine use but will 
also identify the opportunities of collaborative work to optimize the use of CNS medicines. Keeping 
this in mind, we reviewed the studies reporting the utilization of CNS medicines among residents of 
aged care homes across the globe.  
2. Methods 
2.1. Scope of Review: Eligibility Criteria 
The systematic review process was conducted following PRISMA guidelines [11]. To determine 
the proportions (with 95% CI) of CNS drugs use in the aged care homes, a literature search was 
performed using scientific databases to identify cross-sectional surveys (and prospective or 
retrospective studies presenting frequencies and percentages) published in full between 1 January 
2000 and 31 December 2018. These had to report the use of CNS medicines in older adults (aged ≥ 60 
years). Studies were required to recruit participants from aged care settings. The eligibility criteria, 
which were defined prospectively, are provided in Box 1. 
Box 1. Eligibility criteria. 
Cross-sectional surveys or observational (prospective or retrospective) studies 
Recruited adults ( > 90% of participants aged ≥ 60 years) 
Participants recruited from the aged care homes 
Reported frequency and/ or percentage of CNS drugs use (total sample and number of users) 
Sample size of ≥ 50 participants 
Broad definition of CNS drugs including psychotropic, antipsychotic, antidepressant, 
benzodiazepines, antiparkinson, and antiepileptic medicines 
2.2. Information Sources 
The following databases were searched: MEDLINE (Medical Literature Analysis and Retrieval 
System Online), EMBASE (Excerpta Medica Database), CINAHL (Cumulative Index of Nursing and 
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Allied Health Literature), Scopus, and IPA (International Pharmaceutical Abstracts). Only articles 
published between 1 January 2000 and 31 December 2018 were included to present more recent 
picture of CNS medicines use at aged care homes. A manual search of the reference lists of the 
identified articles and recent reviews was conducted to retrieve additional publications. 
2.3. Search Strategy 
The search strategy identified research on CNS medicines use in aged care homes. The medical 
literature was searched using the following search terms: aged care home, nursing home, residential 
aged care, or long-term aged care. These were combined using the set operator AND with studies 
identified with the terms: central nervous system medication or central nervous system medicine or 
central nervous system drug or CNS medication or CNS medicine or CNS drug or psychotropic, 
benzodiazepine or antidepressant or antipsychotic, antiparkinson or antiepileptic AND prevalence 
or utilisation or utilization (see Table S1 for details). The search was limited to original journal articles 
and observational studies, involving human subjects, older adults and published in the English 
language. SSH and KA searched the literature, independently to ensure consistency in the results. 
Titles and abstracts were screened to remove studies that were irrelevant to the aim of the review. 
The full texts of the remaining studies were then examined to determine eligibility. 
Two investigators assessed abstracts independently against 5 criteria: (1) studies conducted to 
report the proportions of CNS drugs use; (2) studies conducted in aged care facilities; (3) cross-
sectional surveys or observational (prospective or retrospective) studies; (4) included older adults in 
care homes; and (5) encompassed patients with a range of CNS related diseases. Full papers of 
potential studies were independently assessed by the two investigators for their suitability.  
2.4. Data Extraction 
One of the authors extracted data independently on to a Microsoft Excel spreadsheet (XP 
Professional edition; Microsoft, Redmond, Washington, DC, USA) that was verified by the second 
reviewer. The following data were collected for each study: the name of the first author; country; 
publication year; study design; duration of the study; number of subjects, and number of females; 
age of the subjects; any inclusion criteria; types of CNS medicines; description of the CNS related 
diseases; number of participants; and number of CNS medicine users (see supplementary file).  
2.5. Assessment of Quality in Included Studies 
The lead author independently assessed the quality each of the included studies and discussed 
their assessments with other two authors to achieve consensus. Each observational study was 
evaluated against the Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist for 
Observational Studies and ranked in terms of deficiencies [12]. The checklist used to assess the quality 
of studies based on six standard criteria (domains): internal validity; selection of subjects; assessment; 
confounding; statistical analysis; and overall assessment of the study. The investigators made 
judgments (using the options, yes, no, can’t say, and doesn’t apply) to indicate whether the studies 
met the particular criterion. 
2.6. Data Synthesis and Statistical Analysis 
The primary outcome or focus of this review was to report the frequency and proportion of CNS 
drugs use. Pooled estimate or proportion was defined as the number of persons using CNS drugs at 
a given time divided by the total number of persons who participated in the study. The proportion 
of individuals using medicines affecting CNS in each study, was combined to give a pooled estimate 
for all studies. The primary analysis reports an overall use of CNS drugs, whereas subgroup analysis 
reports the use of individual therapeutic group (e.g., antidepressants, antipsychotics). Heterogeneity 
between studies was assessed using the I2 statistic with a cut-off of 50%, and the χ2 test with a p value 
< 0.10, used as the threshold for statistically significant heterogeneity. Subgroup analyses were 
conducted according to individual country and geographical region. Data were pooled using MetaXL 
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V.5.3 [13] to generate forest plots of pooled estimates with 95% CIs. MetaXL uses untransformed, 
logit transformed and double arcsine transformed prevalence, with the double arcsine 
transformation, a default option in MetaXL, was employed in this study [13]. 
3. Results 
3.1. Characteristics of the Included Studies 
The search yielded 17,683 titles from the selected databases. After removal of duplicate records, 
and titles screening, 313 full-texts articles were retained for further evaluation (see Figure 1). In the 
end, 89 articles met the inclusion criteria and were selected. Detailed characteristics of all included 
studies are provided in online supplementary Table S2. The majority of studies were conducted in 
Europe (n = 32), Scandinavia (n = 23), North America (n = 17), and Australia-New Zealand (ANZ) (n 
= 15) with a minority of the studies from South East Asia (n = 2, Singapore and Malaysia). Most studies 
were published from the US (n = 12) followed by Australia (n = 11) and Norway (n = 10). There were 
few studies from Asia and no studies from Africa, South and Central America. 
 
Figure 1. Study selection process (PRISMA). 
3.2. Trends in Global Use of CNS Drugs 
The CNS drugs use in the aged care settings, when data from all 89 separate study populations 
were pooled, was 35.0% (95% CI 33.1% to 36.8%) (Table 1). The pooled estimate of CNS drugs use in 
2001 was 27.5% (95% CI 12.0% to 61.9%) and 31.4% (95% CI 20.5% to 43.5%) in 2018. The pooled 
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estimate of CNS drugs use in individual countries is provided in Figure 2, and the pooled estimate 
of CNS drugs use according to geographical study location is provided in Table 1. There was 
statistically significant heterogeneity between studies in all of these analyses (see supplementary file, 
Figure S1–S4). The highest percentage of CNS drugs use occurred in Scandinavia, parts of Europe 
(42.5%; 95% CI 39.8% to 45.3%) and the lowest in North America (31.7%; 95% CI 27.8% to 35.7%). 
Table 2 presents the pooled estimate of overall CNS drugs use among aged care homes residents by 
countries. The highest pooled percentage of CNS drugs use was in Belgium (49.0%; 95% CI 37.5% to 
60.4%) followed by Finland (44.8%; 95% CI 37.9% to 51.8%) and Austria (44.3%; 95% CI 33.6% to 
55.2%). 
Table 1. Pooled proportion of any CNS medicine use according to geographical location. 
Region Studies (n) Pooled Proportion (%) 95% CI (%) I2 (%) p-Value for I2 
Scandinavia 23 42.5 39.8–45.3 99.4 <0.001 
Europe 32 41.2 36.0–46.6 99.8 <0.001 
South East Asia 2 38.2 13.8–65.8 97.4 <0.001 
ANZ 15 34.3 28.1–40.8 99.7 <0.001 
North America 17 31.7 27.8–35.7  99.9 <0.001 
All studies 89 35.0 33.1–36.8 99.9 <0.001 
ANZ = Australia & New Zealand. 
 
Figure 2. Overall CNS drugs use among care homes residents (countries with at least 2 studies). 
Table 2. Overall CNS drugs use among care homes residents by countries. 
Country No. Studies Pooled Proportion (%) 95% CI (%) 
Belgium 4 49.0  37.5–60.4 
Finland 4 44.8  37.9–51.8 
Austria 3 44.3  33.6–55.2 
France 4 41.3  30.1–52.9 
Sweden 9 38.9  30.0–48.2 
Norway 10 38.7  31.6–46.0 
Spain 2 37.0  19.5–56.3 
US 12 31.7  26.9–36.7 
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Australia 11 31.7  24.6–39.3 
New Zealand 4 31.3  15.1–49.9 
Canada 5 30.0  23.3–37.3 
Italy 5 27.7  9.5–50.3 
Germany 3 25.1  14.1–38.0 
UK 5 22.3  16.5–28.7 
Ireland 2 20.3 14.7–26.6 
Countries (Singapore, Malaysia, Switzerland, Slovenia, and the Netherlands) with only one study 
were excluded. 
3.3. Use of Psychotropic Drugs 
The overall pooled estimate of psychotropic drugs use from 32 studies was 68.0% (95% CI 65.7% 
to 70.2%), with the highest percentage in Europe (72.2%) and lowest in ANZ region (56.9%) (Table 3). 
Overall, more than half of the residents of aged care homes were prescribed with psychotropic drugs 
as shown in Figure 3, with the highest percentage of 79.7% reported in a study conducted in Finland 
[14]. The highest pooled estimate (78.0%; 95% CI 74.2% to 81.6%) was in Finland, followed by Belgium 
(77.2%; 95% CI 72.9% to 81.2%) (Table 4).  
Table 3. CNS medicines use according to therapeutic classification and geographic classification. 
Drug Studies (n) Pooled Proportion (%) 95% CI (%) I2 (%) p-Value for I2 
Psychotropic drugs 32 68.0 65.7–70.2 98.5 <0.001 
Europe 10 72.2 67.1–77.1 99.0 0.001 
Scandinavia 10 71.6 69.2–74.0 91.0 0.001 
North America 3 69.3 65.0–73.6 98.0 0.001 
ANZ 9 56.9 52.2–61.4 98.0 0.001 
Antipsychotics 57 26.1 25.1–27.2 99.6 <0.001 
Europe 18 27.7 23.9–31.6 99.0 <0.001 
Scandinavia 14 26.3 22.8–30.0 98.0 <0.001 
North America 15 24.6 22.7–26.6 100 <0.001 
ANZ 10 23.5 20.7–26.4 96.0 <0.001 
Antidepressants 47 38.3 35.1–41.6 99.7 <0.001 
North America 10 44.9 35.3–54.5 100.0 <0.001 
Scandinavia 18 41.0 39.2–42.9 93.0 0.001 
Europe 13 33.5 29.3–37.7 99.0 <0.001 
ANZ 6 30.5 23.6–37.7 96.0 0.001 
Benzodiazepines 70 36.2 32.2–40.4 99.8 <0.001 
Europe 14 44.8 38.4–51.2 100 <0.001 
Scandinavia 18 42.3 37.8–46.8 99.0 <0.001 
ANZ 8 29.4 21.1–38.2 99.0 <0.001 
North America 9 18.9 13.5–24.8 99.0 <0.001 
Antiepileptics 17 10.8 9.1–12.6 98.4 <0.001 
Antiparkinsons 4 6.5 5.2–8.0 79.0 0.003 
Note: ANZ = Australia & New Zealand; North America included US and Canada. 
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Figure 3. Use of psychotropic, antipsychotic, antidepressant and benzodiazepine drugs among care 
homes residents (countries with at least 2 studies were included). 
Table 4. Use of different CNS drugs by residents of care homes by countries. 
Country No. Studies Drug Class Pooled Proportion (%) 95% CI (%) 
Australia 
5 Psychotropic 60.2 54.5–65.8 
7 Antipsychotic 24.8 21.3–28.5 
5 Antidepressant 30.6 21.8–40.1 
6 Benzodiazepine 27.4 17.4–38.7 
Austria 
2 Antipsychotic 45.9 44.3–47.5 
2 Antidepressant 36.8 35.3–38.4 
2 Benzodiazepine 35.0 33.5–36.5 
Belgium 
2 Psychotropic 77.2 72.9–81.2 
2 Antipsychotic 24.2 10.6–41.0 
3 Antidepressant 40.3 38.8–41.8 
3 Benzodiazepine 54.1 51.8–56.4 
Canada 
5 Antipsychotic 28.6 24.5–32.9 
3 Antidepressant 27.7 8.9–51.2 
4 Benzodiazepine 23.9 12.3–37.7 
Finland 
2 Psychotropic 78.0 74.2–81.6 
6 Antipsychotic 37.0 31.9–42.2 
4 Antidepressant 43.3 41.2–45.5 
4 Benzodiazepine 40.8 26.6–55.8 
3 Antiepileptic 10.8 6.5–15.9 
France 
3 Antipsychotic 26.0 23.8–28.3 
2 Antidepressant 43.3 42.2–44.5 
2 Benzodiazepine 48.4 38.4–58.4 
Germany 2 Antipsychotic 31.6 25.0–38.7 
Italy 3 Antiepileptic 13.5 3.5–28.0 
New Zealand 
4 Psychotropic 52.5 40.4–64.4 
3 Antipsychotic 20.3 16.6–24.4 
2 Antidepressant 25.4 16.5–35.5 
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2 Benzodiazepine 35.1 32.6–37.7 
Norway 
8 Psychotropic 70.4 68.0–72.8 
10 Antipsychotic 23.5 22.5–24.5 
12 Antidepressant 38.7 35.5–42.0 
10 Benzodiazepine 44.8 39.2–50.4 
3 Antiepileptic 9.8 7.2–12.7 
Spain 2 Benzodiazepine 41.4 32.2–50.9 
Sweden 
4 Psychotropic 70.1 67.7–72.5 
5 Antipsychotic 20.3 16.4–24.7 
8 Antidepressant 43.9 41.2–46.6 
4 Benzodiazepine 37.1 34.0–40.3 
UK 
5 Antipsychotic 18.9 17.5–20.3 
2 Antidepressant 35.3 30.1–40.7 
US 
2 Psychotropic 71.2 68.1–74.1 
10 Antipsychotic 22.8 20.7–24.9 
7 Antidepressant 52.0 43.2–60.7 
5 Benzodiazepine 14.7 8.8–21.8 
Note: Countries with a minimum of 2 studies were included. 
3.4. Use of Antipsychotic Drugs 
Approximately a quarter of residents in aged care homes from 57 studies received treatment 
with antipsychotic drugs (26.1%; 95% CI 25.1% to 27.2%) (Table 3). The utilisation differed according 
to geographical regions: from 23.5% (95% CI 20.7% to 26.4%) in ANZ to 27.7% (95% CI 23.9% to 31.6%) 
in Europe (Table 3 & Figure 3). The highest percentage reported was 45.9% in a study conducted in 
Austria [15,16]. The highest pooled percentage (45.9%) was in Austria, followed by Finland (37.0%) 
(Table 4). 
3.5. Use of Antidepressant Drugs 
The pooled estimate of antidepressants use from 47 studies was 38.3% (95% CI 35.1% to 41.6%) 
(Table 3). The utilisation according to geographical regions were as follows: 44.9% in North America, 
41.0% in Scandinavia, 33.5% in Europe, and 30.5% in ANZ (Table 3 & Figure 3). The highest 
percentage reported was 59.8% in a study conducted in the US [17]. The highest pooled percentage 
(52.0%) was in the US, followed by Sweden (43.9%) (Table 4). 
3.6. Use of Benzodiazepines 
The pooled estimate of benzodiazepines use from 70 studies was 36.2% (95% CI 32.2% to 40.4%) 
(Table 3). The percentage use of benzodiazepines varied widely from 18.9% in North America (n = 9) 
to 44.8% in Europe (n = 14) (Table 3 & Figure 3). The highest percentage reported was 64.2% in a study 
conducted in the Netherlands [18]. The highest pooled percentage (54.1%) was in Belgium, followed 
by France (48.4%) (Table 4). 
3.7. Use of Antiepileptic and Antiparkinson Drugs 
The pooled estimate of antiepileptic drugs use from 17 studies was 10.8% (95% CI 9.1% to 12.6%) 
(Table 3). The use did not vary greatly among the countries with a range of 9.8% in Norway to 13.5% 
in Italy. Only four studies met the criteria that reported the proportion of antiparkinson drugs among 
aged care home residents. The pooled estimate of antiparkinson drugs use was 6.5% (95% CI 5.2% to 
8.0%) (Table 3). 
4. Discussion 
This systematic review with meta-analysis has assembled data from 89 population-based 
studies, reporting the proportion of CNS drugs use in the aged care homes. We found a relatively 
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high prevalence of CNS drugs use in aged care home in most of the regions specially Scandinavia, 
Europe and North America. The proportion of CNS drugs use varied, from 31.7% to over 42.5%, 
according to the geographical location of the population under study, with an overall proportion of 
CNS drugs use of 35.0%. A higher proportion of residents in aged care homes in European and 
Scandinavian regions were using psychotropic medicines while the use of antipsychotic drugs did 
not vary greatly across geographical regions. There were no studies from African or South American 
countries, and it is possible that studies identified in this search were conducted in countries where 
the culture of having elderly adults in nursing homes is acceptable, such as in the United States of 
America (US), Europe, ANZ and some Asian countries; whereas, in developing regions, older adults 
are cared for by family members. 
In this study, the overall pooled estimate of psychotropic drugs use from 32 studies was 68.0%. 
This high percentage of psychotropic medicines use in aged care homes compared with the normal 
population is of great importance from both policy making point of view as well as clinical point of 
view. CNS drugs use is justified as these medicines treat a number of mental disorders such as 
depression, psychiatric and mood disorders. Hence, one would argue that from policy making point 
of view they should be relatively easy to be prescribed and dispensed to treat depression, aggression, 
mood disorders, etc. to ensure well-being of aged care homes’ residents. From a clinical point of view 
these medicines may produce adverse effects, particularly in long-term therapy and in older frail 
adults who are taking number of other medications for their chronic conditions. Moreover, with 
ageing comes pharmacokinetic changes, which would mean the need for dose adjustment to avoid 
toxicity, monitoring drug-drug interactions, monitoring drug-disease interactions, etc. [19]  
4.1. Trend in the Global Use of CNS Drugs 
Scandinavia and Europe (Belgium and Austria) had the highest pooled proportion of any CNS 
medicine use. Increased prevalence of CNS drugs use and high volume prescriptions of CNS drugs 
such as benzodiazepines and antiepileptic drugs have been reported in Norway, Austria and 
Belgium. [19–23].  
Studies have suggested variety of reasons for persistent use of CNS drugs in aged care home. 
Management of neuropsychiatric symptoms—behavioral symptoms, for instance, has been 
associated with frequent psychotropic drugs prescription [21,22]. Prescribers’ behavior has been 
suggested as another reason for high prevalence of benzodiazepines use among aged care home 
residents [20]. Lack of communication between general practitioners (GPs) and nurses has 
contributed towards high prevalence of CNS drugs use in Belgian aged care homes [23]. In an attempt 
to broadly classify the reasons for high prevalence of CNS drugs prescription in aged care homes, we 
can categorize them into (a) patients characteristics/needs and (b) policies implementation. 
It has been reported that high prevalence of certain conditions such as dementia is associated 
with high prevalence of CNS drugs use [21,24]. To control behavioral symptoms and pain one would 
think it is in patient’s interest—as well as in the interest of other residents of aged care homes—to 
ensure patients receive their medication seemingly. However, it has also been reported that in the 
process of CNS drugs prescription and dispensing, sometimes, guidelines and policies of managing 
medicines in aged care homes are not fully implemented [20,24]. Healthcare professionals could 
mentally juggle between patient’s want and patient’s interest, especially in dire situations where 
there is an immediate need to intervene to alleviate distress and pain in elderly frail patients/residents 
of aged care homes. 
Nonetheless there are also some good examples of commendable practices of lower than average 
CNS drugs use. Australia-New Zealand and the United Kingdom, for example, had the lowest pooled 
proportion of any CNS medicine use in aged care homes. From clinical point of view these countries 
have adapted a more proactive approach to behavioral symptoms and pain control by ensuring 
timely dose tapering without re-emergence of symptoms. Moreover, they have introduced 
multidisciplinary approach to patient care by including different healthcare professionals to answer 
patients’ needs via both pharmacological and non-pharmacological interventions [25]. Non-
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pharmacological intervention would automatically reduce the volume and frequency of 
pharmacological treatment modalities.  
From policy implementation point of view, detailed guidelines and pragmatic protocols have 
been devised to protect both patients/residents as well as healthcare professionals [26]. Such 
guidelines would serve as a legal framework not to only oblige the healthcare professionals to follow 
the rules; but also, protect everyone especially securing patients/residents of aged care homes’ safety.  
4.2. Benzodiazepines 
Benzodiazepines are one of the most commonly used CNS drugs to treat conditions like 
insomnia and anxiety; however, studies reported that for most residents, no appropriate indication 
was documented [6,27,28]. Most studies carried out on the effect of benzodiazepines on the above 
two indications have been conducted on young adults and limited data are available on long term 
effects and efficacy of these medications [29–32]. Whilst short-term use of benzodiazepines might be 
safe in young adults, its short-term use in elderly patients can have serious adverse effects such as an 
increase in falls and fractures as well as slowed reaction time leading to motor vehicle accidents 
[33,34]. Additionally, benzodiazepines use in the elderly could cause dependence, withdrawal effects 
and long-lasting cognitive decline and can lead to dementia due to the slow rate of metabolism in 
older adults [35,36]. 
Among the benzodiazepines, short-acting agents such as lormetazepam, lorazepam and 
oxazepam were most frequently used by the residents [6,14,37–42]. It should be noted that short-
acting drugs induce a greater risk of withdrawal symptoms as the body has less time to adapt to 
working without them. Duplicate therapy (e.g., patients using two benzodiazepines), which is of 
concern regarding benzodiazepine prescribing, occurred among 13.6% and 9.7% of French [38] and 
Belgian [6] residents, respectively; however, this was nearly four times lower among Italian (3.7%) 
[43] and Spanish (1.9%) [41] residents. These results may have long-reaching implications in clinical 
practice and research related to the management of CNS disorders in older adults. Being aware of 
individuals most at risk will allow clinicians and researchers to direct their efforts in developing 
guidelines more suited to high-risk groups (e.g., those having a greater risk of withdrawal 
symptoms).  
4.3. Antidepressants 
Depression is one of the most common disorders in the elderly population, which has 
historically been undiagnosed and untreated [5]. As the number of older persons is increasing the 
number of elderly patients suffering from mental and neurological disorders including depression is 
also increasing [5]. Depression is associated with functional decline, which could also negatively 
affect other co-morbidities such as stroke; and it could eventually lead to death due to suicide [44]. 
This requires a higher degree of care and the use of care facilities, which may lead to the higher use 
of antidepressants. In choosing an appropriate antidepressant drug for an elderly patient the side 
effect profile and lowest risk of drug interaction must be considered. According to the NICE 
guidelines (CG90) updated in 2016, the first line drug treatments are the selective serotonin reuptake 
inhibitors (SSRIs), which are relatively safe in the elderly [45].  
The safer SSRIs for use in elderly patients are sertraline, citalopram and escitalopram [46–48]. If 
tricyclic antidepressants (TCAs) have to be given which are second line drug treatments, then 
desipramine and nortriptyline are the best choices as they are less anticholinergic [47]. Other tricyclic 
drugs should be avoided due to worsening effect on dementia, Parkinson’s disease, cardiovascular 
problems and postural hypotension which would increase the risk of fall and fractures in elderly 
patients. According to a Cochrane review both SSRIs and tricyclic antidepressants are equally 
effective in the elderly although SSRIs are better tolerated with fewer adverse effects [49]. It should 
also be taken into consideration that older patients take longer to show a response to treatment 
[49,50].  
There was a major change in the pattern of prescribing in aged care homes from the late 1990s, 
when TCAs, particularly amitriptyline and nortriptyline, were largely replaced by SSRIs, especially 
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sertraline, citalopram and escitalopram. The latter became the most frequently used antidepressants 
in aged care homes in most countries such as Belgium [6,27,51], Finland [14], Norway [10,52,53], 
Sweden [54–57], Austria [15], Slovenia [42], US [37,58,59], Singapore [60], as well as ANZ [61–64]. 
However, mirtazapine, which is an atypical antidepressant, was most frequently prescribed in other 
studies conducted in the US and Sweden [17,39]. While in Germany, TCA use was favored [16]. A 
more worrying analysis showed that more than one type of antidepressant was prescribed 
concomitantly in 1% to 8% of aged care residents [6,14,17,43,62,65]. Considering other comorbidities 
that the elderly patients have, there is a high chance of drug-drug interactions and therefore this 
proportion could be a target for improvement. Lack of documentation regarding indications was also 
an issue and in Swedish aged care homes more than half (65.0%) of the antidepressant users had no 
documented indication for treatment [55]. However, in studies conducted in Norway and the United 
Kingdom (UK), aged care homes reported this percentage to be less than 15.4% and 42.5%, 
respectively [17,66]. It is worth noting that under-treatment of depression was also documented in 
some studies, in which at least one quarter of depressed residents did not receive any antidepressant 
medicine [17,55,66]. It was not also clear whether patients received any non-pharmacological 
cognitive therapy in addition or prior to the drug therapy. These findings reinforce the need for 
rational guidelines to optimize therapy with antidepressants and medicine management of 
depression among residents in aged care homes. 
4.4. Antipsychotics 
In recent years the use of typical or conventional antipsychotics with a strong antagonistic effect 
on dopamine D2 receptors, have been avoided in elderly patients due to their severe adverse effects 
and limited tolerability [67,68]. On the other hand, the atypical antipsychotic medicines with high 
affinity for both serotonergic and dopaminergic receptors and other receptors, have been widely used 
in recent years due to their effectiveness against negative symptoms, their higher efficacy and binding 
profile and more importantly limited extrapyramidal side effects in patients diagnosed with 
schizophrenia, mania and acute psychosis reactions and other psychotic disorders [69–72]. It seems 
that atypical antipsychotics reduce dopamine transmission by acting on the mesocortical pathway 
which leads to anti-psychotic effects, whilst increasing dopamine transmission in the frontal cortex 
and nigrostriatal pathway [72,73]. In addition, the transient binding and dissociation of atypical anti-
psychotics to D2 receptors would lead to a normal transmission of dopamine, which would make a 
more suitable option particularly for elderly patients [72,73]. However, even the atypical anti-
psychotics induce some side effects in elderly populations.  
Knowledge of the binding profile and adjusting the dose of antipsychotics play an essential role 
in the effects they mediate or the symptoms they alleviate. For example, risperidone equally blocks 
D2 and 5-HT2 receptors, however, at higher doses of more than 2 mg/day, it has a higher affinity for 
D2 receptors which may facilitate the onset of extrapyramidal side effects in elderly patients [73–75]. 
Ziprasidone blocks more 5-HT2 receptors than D2 receptors and is more effective in reducing 
psychotic symptoms and better tolerated than typical anti-psychotics such as haloperidol, 
particularly in movement disorders [74,76]. Interestingly, its weak anticholinergic effect explains its 
more favorable cognitive profile than typical drugs in elderly patients. The lack of cognitive 
impairment has also been reported by olanzapine which stimulates the release of acetylcholine by 
blocking 5-HT6 receptors [77].  
The main indications for prescribing antipsychotics to residents in aged care homes were 
aggression, agitation, and restlessness associated with dementia [6,42,78,79]. However, a 
documented indication for antipsychotic treatment was absent for 48% of antipsychotic users in a 
study conducted in Sweden [55]. Briesacher et al. reviewed the indications for antipsychotic 
prescribing in American nursing homes during the year of 2000–2001 and found that there was no 
appropriate indication in a lower proportion (23.4%) of antipsychotic users [79]. In another study in 
the US conducted in 2004, the proportion was almost two-fold higher (40.0%) [28]. In Irish nursing 
homes, 51.0% of antipsychotic users were deemed to be “receiving antipsychotics inappropriately” 
[80]. Furthermore, a UK study reported that more than half (54.0%) of the antipsychotic prescriptions 
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in aged care homes were “inappropriate” [81], while two other studies (in France and Belgium) 
revealed that more than two thirds (66.5 to 98.0%) of antipsychotic users were found to have 
“potentially inappropriate prescribing” [78,82]. This was ascribed to a high prevalence of chronic use, 
pointing to a lack of reassessment [78]. Combination antipsychotic therapy, which is problematic, 
was found in 3.5–15% of residents [6,43,65,83].  
4.5. Antiepileptic and Antiparkinson Medicines 
Our meta-analysis raises concerns regarding the undocumented indication for the use of anti-
epileptic drugs (AEDs) in aged care home residents. This was illustrated in Germany, where the 
indication for AED use was missing in one quarter of residents receiving AEDs [84]. This figure was 
higher in Austria, where an indication for AED use could not be ascertained in 39% of residents [85]. 
Compared to studies in the US and European countries, which reported percentages of less than 50%., 
more than three quarters of residents in Singaporean homes received AEDs without proper 
documentation of a therapeutic indication [60]. 
In prescribing anti-epileptic drugs to elderly patients, clinical practitioners should consider the 
adverse effects and drug-drug interactions. The majority of anti-epileptic drugs interact with other 
medications as well as hepatic enzymes and plasma proteins. Newer anti-epileptic drugs such as 
gabapentin, tiagabine and levetiracetam have minimum interaction and, therefore, are safer for 
elderly patients [86,87]. Although the International League Against Epilepsy Guidelines recommend 
newer AEDs, such as lamotrigine and gabapentin, for elderly adults, most AEDs used in the studies 
in this review were contrary to evidence-based recommendations. Older AEDs, such as phenobarbital 
were used most frequently in aged care homes in Italy [88,89], while carbamazepine was most 
frequently used in Norwegian (21.4%) [19], German (37.0%) [84], and Swedish homes (32.0%) [90]. 
Gabapentin was the most frequently used AED (37.0%) in Austrian aged care homes [85]. 
It is well-known that AEDs are frequently implicated in drug-drug interactions, attributed to 
their complex pharmacokinetic properties. Therefore, it is not surprising that a recent study (2016) 
from Norway reported that drug-drug interactions were observed in nearly half (45%) of AED users 
in aged care home [19]. Efforts should be made to implement rational therapy guidelines and 
optimize drug management of neurological and psychiatric disorders among residents of aged care 
home residents as they represent the frailest segment of the geriatric population. Additional studies 
are needed to determine the use of CNS medications, particularly in Asian countries.  
Only four studies reporting the use of antiparkinson drugs were included in this study showing 
a pooled estimate of 6.5% (95% CI 5.25 to 8.0%). Antiparkinson drugs work very well for the majority 
of patients at the beginning of their therapy; however, this may change over time and side effects, 
such as wearing–off and dyskinesia, hallucinations and delusions, orthostatic hypotension and 
impulsive and compulsive behavior can occur. Upon initiation of the treatment for Parkinson’s 
disease in elderly patients the cognitive issues and comorbidities should be considered. The initial 
treatments are with dopamine agonists and levodopa [91]. The optimum dose for each patient might 
vary and should be identified as a dose that works the best for each elderly patient. The optimum 
dose of levodopa tends to remain constant over the years although more frequent doses might be 
required to counteract levodopa wearing-off effects but not higher individual doses [92]. The ceiling 
dose should not be exceeded, as beyond which there is no further benefit. Clinicians can escalate the 
dose to capture the most benefit for any elderly patient [93].  
5. Conclusions 
The present meta-analysis has demonstrated that a significant proportion of older people 
residing in care homes consumed CNS medicines with psychotropic medicines being the most 
commonly used medicines. The overall use of CNS drugs varied among countries, with studies from 
Australia-New Zealand reporting the lowest use of CNS drugs. Elderly patients in care homes are 
amongst the most vulnerable members in society who rely on care home staff for their everyday 
needs. There is always a risk in the use of medications in the elderly population due to the changes 
in the metabolism, which alter the pharmacodynamics and pharmacokinetics of drugs, increasing the 
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risk of interactions particularly due to the frequency of polypharmacy in these patients. Therefore, 
careful balance between treating safely and adequately should be considered to avoid further 
comorbidity and risk of death in older populations. Careful monitoring is needed for adverse effects 
and attention should be given to some medications which may also cause harm. The criteria for 
prescribing these medications in clinical practice should be evidence-based. The criteria should be 
used not to prohibit the use of the listed medications but to support the clinical judgement. The 
quality of evidence, potential for harm and availability of safer alternatives should be considered. 
Educating the patients can play an important first step in tapering protocols for medications such as 
benzodiazepines for safe and comfortable discontinuation of the medication. Future studies should 
focus on strategies for the development of specific guidelines for aged care homes residents receiving 
CNS drugs. 
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